Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
62.97
+3.13 (5.23%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Rhythm Pharmaceuticals stock have an average target of 74.92, with a low estimate of 65 and a high estimate of 92. The average target predicts an increase of 18.98% from the current stock price of 62.97.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 8 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $63 → $68 | Strong Buy | Maintains | $63 → $68 | +7.99% | Apr 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 → $80 | Strong Buy | Reiterates | $70 → $80 | +27.04% | Apr 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $81 → $92 | Strong Buy | Maintains | $81 → $92 | +46.10% | Apr 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +4.81% | Apr 8, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $80 → $91 | Buy | Maintains | $80 → $91 | +44.51% | Apr 7, 2025 |
Financial Forecast
Revenue This Year
187.17M
from 130.13M
Increased by 43.84%
Revenue Next Year
310.00M
from 187.17M
Increased by 65.62%
EPS This Year
-2.68
from -4.34
EPS Next Year
-1.45
from -2.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 202.0M | 420.0M | 686.8M | ||
| Avg | 187.2M | 310.0M | 562.3M | ||
| Low | 174.4M | 245.5M | 412.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 55.2% | 124.4% | 121.6% | ||
| Avg | 43.8% | 65.6% | 81.4% | ||
| Low | 34.1% | 31.2% | 33.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.06 | -0.40 | 3.31 | ||
| Avg | -2.68 | -1.45 | 1.89 | ||
| Low | -3.09 | -2.38 | 1.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.